Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

• Published in: Cancer science Vol. 110; no. 4; pp. 1480 - 1490
• Main Authors: Sunami, Kuniko, Ichikawa, Hitoshi, Kubo, Takashi, Kato, Mamoru, Fujiwara, Yutaka, Shimomura, Akihiko, Koyama, Takafumi, Kakishima, Hiroki, Kitami, Mayuko, Matsushita, Hiromichi, Furukawa, Eisaku, Narushima, Daichi, Nagai, Momoko, Taniguchi, Hirokazu, Motoi, Noriko, Sekine, Shigeki, Maeshima, Akiko, Mori, Taisuke, Watanabe, Reiko, Yoshida, Masayuki, Yoshida, Akihiko, Yoshida, Hiroshi, Satomi, Kaishi, Sukeda, Aoi, Hashimoto, Taiki, Shimizu, Toshio, Iwasa, Satoru, Yonemori, Kan, Kato, Ken, Morizane, Chigusa, Ogawa, Chitose, Tanabe, Noriko, Sugano, Kokichi, Hiraoka, Nobuyoshi, Tamura, Kenji, Yoshida, Teruhiko, Fujiwara, Yasuhiro, Ochiai, Atsushi, Yamamoto, Noboru, Kohno, Takashi
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.04.2019; John Wiley and Sons Inc
• Subjects: actionable gene aberration; Adult; Aged; Biomarkers, Tumor; Cancer; Cancer therapies; Clinical medicine; clinical sequencing; Clinical trials; Computational Biology - methods; Consent; Deoxyribonucleic acid; DNA; DNA Copy Number Variations; Drugs; Female; Gene Expression Profiling - methods; gene panel test; Genes; Genes, Neoplasm; Genetic counseling; Genomics; Genomics - methods; High-Throughput Nucleotide Sequencing; Hospitals; Humans; Impact tests; insurance reimbursement; Laboratories; Male; Middle Aged; Molecular Targeted Therapy; Mutation; NCC Oncopanel; Neoplasms - diagnosis; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - mortality; Next-generation sequencing; Oncology; Original; Patients; Physicians; Prognosis; R&D; Research & development; Solid tumors; Studies; Treatment Outcome; Tumors; United States > US; Japan; clinical sequencing; NCC Oncopanel; gene panel test; actionable gene aberration; insurance reimbursement

Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital‐based prospective study (TOP‐GEAR project, 2nd stage) t...